Wedbush Raises Price Target on Apogee Therapeutics (APGE)

Apogee Therapeutics Inc. (NASDAQ:APGE) is 1 of the 10 astir shorted biotech stocks to bargain according to hedge funds.

On March 3, Wedbush accrued its terms people connected Apogee Therapeutics Inc. (NASDAQ:APGE) from $90 to $95. The steadfast maintained an Outperform standing connected the stock, which yields 30% upside imaginable astatine the existent level.

Apogee Therapeutics Inc. (NASDAQ:APGE) announced its net and reaffirmed its March guidance connected 52-week Phase 2 APEX survey data. The steadfast expects the induction information for the dose-ranging proceedings successful the 2nd 4th of 2026, pursuing the erstwhile exposure-response data. Wedbush expects the Phase 3 trials to statesman successful the 2nd fractional of the year, with further upside from APG279 successful the second half.

On March 2, Apogee Therapeutics Inc. (NASDAQ:APGE) reported a FY25 nett nonaccomplishment of $255.8 million, compared to a nett nonaccomplishment of $182.1 cardinal during the anterior year. Michael Henderson, M.D., Chief Executive Officer, stated:

In the past 12 months we made meaningful advancement crossed our pipeline, including advancing zumilokibart with affirmative APEX Phase 2 Part A results, arsenic good arsenic proof-of-concept information from our Phase 1b proceedings successful asthma, we are present focused connected proving retired the imaginable of zumilokibart successful AD with the APEX Phase 2 Part A 52-week attraction readout expected successful March, followed by the APEX Phase 2 Part B dose optimization readout expected successful the 2nd 4th and Phase 3 initiation targeted by twelvemonth end. Later this year, we program to supply further details connected improvement for enlargement indications including asthma and EoE, further advancing our imaginativeness for zumilokibart arsenic a pipeline-in-a-product. In the 2nd fractional of 2026, our expected head-to-head readout of APG279 compared to DUPIXENT has imaginable to beryllium the archetypal proof-of-concept for Apogee’s operation programs successful AD. With a currency runway into the 2nd fractional of 2028, we judge we are good positioned to enactment toward launching a transformative therapy this decennary arsenic we physique a starring I&I biotech.

Apogee Therapeutics Inc. (NASDAQ:APGE) is simply a clinical-stage biotechnology institution that develops caller biologics to cure inflammatory and immune diseases. These see atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis, and others. Its existing pipeline includes APG777, APG279, APG990, APG333, and APG808, each successful antithetic objective proceedings stages.

While we admit the imaginable of APGE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.